CL2015003370A1 - Derivados de sulfamoilpirrolamiday su uso como medicamentos para el tratamiento de la hepatitis b - Google Patents

Derivados de sulfamoilpirrolamiday su uso como medicamentos para el tratamiento de la hepatitis b

Info

Publication number
CL2015003370A1
CL2015003370A1 CL2015003370A CL2015003370A CL2015003370A1 CL 2015003370 A1 CL2015003370 A1 CL 2015003370A1 CL 2015003370 A CL2015003370 A CL 2015003370A CL 2015003370 A CL2015003370 A CL 2015003370A CL 2015003370 A1 CL2015003370 A1 CL 2015003370A1
Authority
CL
Chile
Prior art keywords
hepatitis
treatment
sulfamoylpirrolamiday
medicines
derivatives used
Prior art date
Application number
CL2015003370A
Other languages
English (en)
Inventor
Koen Vandyck
Geerwin Yvonne Paul Haché
Stefaan Julien Last
Gowan David Craig Mc
Geert Rombouts
Wim Gaston Verschueren
Pierre Jean-Marie Bernard Raboisson
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of CL2015003370A1 publication Critical patent/CL2015003370A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

COMPUESTOS DERIVADOS DE SULFAMOILPIRROLAMIDA; COMPOSICION FARMACEUTICA QUE LOS COMPRENDE; Y PRODUCTO QUE CONTIENE A UNO DE ESTOS COMPUESTOS JUNTO A OTRO INHIBIDOR DEL VIRUS DE LA HEPATITIS B (VHB) COMO UN PREPARARDO COMBINADO PARA EL USO EN EL TRATAMIENTO DE INFECCIONES PROVOCADAS POR EL VHB.
CL2015003370A 2013-05-17 2015-11-16 Derivados de sulfamoilpirrolamiday su uso como medicamentos para el tratamiento de la hepatitis b CL2015003370A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP13168291 2013-05-17
EP13175181 2013-07-04
EP13182281 2013-08-29
EP13191209 2013-10-31
EP13198160 2013-12-18
EP14157900 2014-03-05

Publications (1)

Publication Number Publication Date
CL2015003370A1 true CL2015003370A1 (es) 2016-05-27

Family

ID=50884356

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003370A CL2015003370A1 (es) 2013-05-17 2015-11-16 Derivados de sulfamoilpirrolamiday su uso como medicamentos para el tratamiento de la hepatitis b

Country Status (35)

Country Link
US (3) US9884818B2 (es)
EP (3) EP3121164B1 (es)
JP (3) JP6318238B2 (es)
KR (4) KR101867898B1 (es)
CN (2) CN110003076A (es)
AU (4) AU2014267220B2 (es)
BR (1) BR112015028461A2 (es)
CA (1) CA2909348C (es)
CL (1) CL2015003370A1 (es)
CY (2) CY1121391T1 (es)
DK (2) DK2997011T3 (es)
EA (1) EA037378B1 (es)
EC (1) ECSP15048122A (es)
ES (2) ES2787704T3 (es)
GT (1) GT201500312A (es)
HK (1) HK1218117A1 (es)
HR (2) HRP20181544T1 (es)
HU (2) HUE039997T2 (es)
IL (2) IL260597B (es)
JO (2) JO3603B1 (es)
LT (2) LT3121164T (es)
ME (1) ME03787B (es)
MX (3) MX2020011810A (es)
NI (1) NI201500161A (es)
PH (2) PH12015502579A1 (es)
PL (2) PL3121164T3 (es)
PT (2) PT3121164T (es)
RS (2) RS58140B1 (es)
SG (4) SG10201607293UA (es)
SI (2) SI3121164T1 (es)
TW (4) TWI684586B (es)
UA (1) UA117246C2 (es)
UY (1) UY35573A (es)
WO (1) WO2014184350A1 (es)
ZA (1) ZA201508443B (es)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX359634B (es) 2011-12-21 2018-10-03 Novira Therapeutics Inc Agentes antivirales contra la hepatitis b.
BR112015004192B1 (pt) 2012-08-28 2021-02-09 Janssen Sciences Ireland Uc sulfamoíl-arilamidas, composição farmacêutica que os compreende e uso das mesmas no tratamento da hepatite b
JP6466348B2 (ja) 2013-02-28 2019-02-06 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用
DK2981536T3 (en) 2013-04-03 2017-09-25 Janssen Sciences Ireland Uc N-PHENYLC CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
HUE063817T2 (hu) 2013-05-17 2024-01-28 Incyte Holdings Corp Bipirazol-származékok mint JAK inhibitorok
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
CN105960400B (zh) 2013-05-17 2019-05-31 爱尔兰詹森科学公司 氨磺酰基噻吩酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
EP3357906B1 (en) 2013-07-25 2019-12-04 Janssen Sciences Ireland Unlimited Company Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
CA2923712C (en) 2013-10-23 2021-11-02 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
AU2015214096B2 (en) 2014-02-05 2021-02-11 Novira Therapeutics, Inc. Combination therapy for treatment of HBV infections
CA2932551A1 (en) 2014-02-06 2015-08-13 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
HUE046567T2 (hu) 2014-03-13 2020-03-30 Univ Indiana Res & Tech Corp Hepatitis B mag protein allosztérikus modulátorok
EP3271019A1 (en) 2015-03-19 2018-01-24 Novira Therapeutics Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
WO2016161268A1 (en) 2015-04-01 2016-10-06 Enanta Pharmaceuticals, Inc. Hepatitis b antviral agents
WO2016183266A1 (en) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Ehpatitis b antiviral agents
US10875876B2 (en) * 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2017011552A1 (en) 2015-07-13 2017-01-19 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
PL3324977T3 (pl) 2015-07-22 2022-11-14 Enanta Pharmaceuticals, Inc. Pochodne benzodiazepiny jako inhibitory rsv
US10301255B2 (en) 2015-07-22 2019-05-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
TWI730985B (zh) 2015-09-15 2021-06-21 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
CA3000197A1 (en) 2015-09-29 2017-04-06 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
CN108699077B (zh) 2016-01-15 2021-03-02 英安塔制药有限公司 作为rsv抑制剂的杂环化合物
WO2017136403A1 (en) 2016-02-02 2017-08-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
CN109069488B (zh) 2016-03-07 2021-09-07 英安塔制药有限公司 乙型肝炎抗病毒剂
PE20190118A1 (es) 2016-03-09 2019-01-16 Univ Emory Eliminacion del virus de la hepatitis b con agentes antivirales
CN109640980A (zh) 2016-04-15 2019-04-16 诺维拉治疗公司 包含壳体装配抑制剂的组合和方法
SG11201809893WA (en) 2016-05-27 2018-12-28 Gilead Sciences Inc Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors
JP2019521972A (ja) 2016-06-10 2019-08-08 エナンタ ファーマシューティカルズ インコーポレイテッド Ｂ型肝炎抗ウイルス剤
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CN109923106B (zh) 2016-09-02 2022-09-13 吉利德科学公司 toll样受体调节剂化合物
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
CN109937201A (zh) 2016-09-15 2019-06-25 组装生物科学股份有限公司 乙型肝炎核心蛋白调节剂
SG11201903042VA (en) 2016-10-14 2019-05-30 Precision Biosciences Inc Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
SG11201902944TA (en) 2016-11-07 2019-05-30 Arbutus Biopharma Corp Substituted pyridinone-containing tricyclic compounds, and methods using same
EA037576B1 (ru) * 2016-11-11 2021-04-15 Новира Терапьютикс, Инк. Комбинации и способы, включающие ингибитор сборки капсида
CN108264520B (zh) * 2017-01-03 2021-12-07 上海长森药业有限公司 用于治疗乙型肝炎的化合物及其用途
US10398706B2 (en) 2017-01-06 2019-09-03 Enanta Pharmaceuticals, Inc. Heteroaryldiazepine derivatives as RSV inhibitors
CN108341810B (zh) * 2017-01-23 2022-01-18 上海长森药业有限公司 环硫脲类化合物及其用途
CN108341817B (zh) * 2017-01-23 2021-11-26 上海长森药业有限公司 硫脲类、脲类化合物及其用途
TWI820984B (zh) 2017-01-31 2023-11-01 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
CN110809472B (zh) 2017-02-16 2023-05-23 英安塔制药有限公司 用于制备苯二氮䓬衍生物的方法
WO2018153326A1 (zh) * 2017-02-22 2018-08-30 上海长森药业有限公司 磺酰肼类化合物及其用途
EP3589630B1 (en) 2017-03-02 2021-07-07 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same
MA49014A (fr) 2017-03-21 2020-02-05 Arbutus Biopharma Corp Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
JP7123429B2 (ja) * 2017-05-04 2022-08-23 シャンハイ ロングウッド バイオファルマシューティカルズ カンパニー リミテッド 二環式縮合環系ヌクレオカプシド阻害剤および薬物としてｂ型肝炎を治療するためのその使用
WO2018226801A1 (en) 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as rsv inhibitors
WO2019006291A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
AU2018326474A1 (en) 2017-08-28 2020-04-16 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
CA3077309A1 (en) 2017-09-29 2019-04-04 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as rsv inhibitors
WO2019094920A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as rsv inhibitors
CA3080138A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives
US10723733B2 (en) 2017-12-06 2020-07-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2019113173A1 (en) 2017-12-06 2019-06-13 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
AU2018392212B9 (en) 2017-12-20 2021-03-18 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
CN111601788B (zh) * 2018-02-09 2022-06-14 正大天晴药业集团股份有限公司 衣壳蛋白装配抑制剂、其药物组合物和用途
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
BR122023022189A2 (pt) 2018-02-16 2024-02-20 Incyte Corporation Usos de inibidores da via de jak1 para o tratamento de distúrbios relacionados a citocinas
US10836769B2 (en) 2018-02-26 2020-11-17 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
MX2020009531A (es) 2018-03-14 2020-10-05 Janssen Sciences Ireland Unlimited Co Regimen posologico del modulador del ensamblaje de la capside.
US10729688B2 (en) 2018-03-29 2020-08-04 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
CN113768934A (zh) 2018-03-30 2021-12-10 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
SG11202009150RA (en) 2018-03-30 2020-10-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
EP3774883A1 (en) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
JP7296398B2 (ja) 2018-04-06 2023-06-22 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． ３’３’－環状ジヌクレオチド
US10975094B2 (en) 2018-04-11 2021-04-13 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
US11459296B2 (en) 2018-05-16 2022-10-04 Infex Therapeutics Limited Antibacterial compounds
AU2019301811B2 (en) 2018-07-13 2022-05-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
UY38383A (es) 2018-09-21 2020-04-30 Enanta Pharm Inc Heterociclos funcionalizados como agentes antivirales
SG11202104086PA (en) 2018-10-22 2021-05-28 Assembly Biosciences Inc 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CN112969505B (zh) 2018-10-31 2023-11-14 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
WO2020087107A1 (en) 2018-10-31 2020-05-07 The University Of Sydney Compositions and methods for treating viral infections
PE20211655A1 (es) 2018-10-31 2021-08-24 Gilead Sciences Inc Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
KR20210093951A (ko) 2018-11-21 2021-07-28 이난타 파마슈티칼스, 인코포레이티드 항바이러스제로서의 작용화된 헤테로사이클
TWI827760B (zh) 2018-12-12 2024-01-01 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
EA202092159A1 (ru) 2019-01-25 2020-12-15 Чиа Тай Тянцин Фармасьютикал Груп Ко., Лтд. Содержащий n-гетероциклическое пятичленное кольцо ингибитор сборки капсидного белка, его фармацевтическая композиция и их применение
US11096931B2 (en) 2019-02-22 2021-08-24 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
DK3934757T3 (da) 2019-03-07 2023-04-17 Inst Of Organic Chemistry And Biochemistry Ascr V V I 2'3'-cykliske dinukleotider og prodrugs deraf
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
MX2021011030A (es) 2019-03-13 2021-10-13 Janssen Sciences Ireland Unlimited Co Formulacion solida del modulador de ensamblaje de la capside.
US11254664B2 (en) 2019-03-18 2022-02-22 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as RSV inhibitors
WO2020210246A1 (en) 2019-04-09 2020-10-15 Enanta Pharmaceuticals, Inc, Heterocyclic compounds as rsv inhibitors
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
CA3132170A1 (en) 2019-04-18 2020-10-22 Michael BIERMER Combination therapy for treating hepatitis b virus infection
US20200332297A1 (en) 2019-04-18 2020-10-22 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
TW202108576A (zh) 2019-05-06 2021-03-01 愛爾蘭商健生科學愛爾蘭無限公司 用於治療ｈｂｖ感染或ｈｂｖ誘發的疾病之醯胺衍生物
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
MA56031A (fr) 2019-05-24 2022-04-06 Assembly Biosciences Inc Compositions pharmaceutiques pour le traitement du vhb
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11472808B2 (en) 2019-06-04 2022-10-18 Enanta Pharmaceuticals, Inc. Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
US20220241402A1 (en) 2019-06-18 2022-08-04 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
WO2020255013A1 (en) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being amide derivatives
WO2020255012A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives
JP7295283B2 (ja) 2019-06-25 2023-06-20 ギリアード サイエンシーズ， インコーポレイテッド Ｆｌｔ３ｌ－ｆｃ融合タンパク質及び使用方法
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
US20230012560A1 (en) * 2019-09-04 2023-01-19 Taigen Biotechnology Co., Ltd. Hepatitis b antiviral agents
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US11497808B2 (en) 2019-09-30 2022-11-15 Gilead Sciences, Inc. HBV vaccines and methods treating HBV
MX2022003984A (es) 2019-10-04 2022-07-27 Enanta Pharm Inc Compuestos heterociclicos antivirales.
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
US20230031465A1 (en) 2019-12-06 2023-02-02 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
US20230151027A1 (en) * 2020-02-11 2023-05-18 Ospedale San Raffaele S.R.L. Spirocyclic inhibitors of hepatitis b virus
TW202146008A (zh) 2020-02-27 2021-12-16 愛爾蘭商健生科學愛爾蘭無限公司 Ｈｂｖ的治療
TW202146011A (zh) 2020-03-05 2021-12-16 美商詹森藥物公司 治療b型肝炎病毒感染之組合療法
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ， インコーポレイテッド ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
WO2021216661A1 (en) 2020-04-22 2021-10-28 Assembly Biosciences, Inc. Pyrazole carboxamide compounds for treatment of hbv
EP4139292A1 (en) 2020-04-22 2023-03-01 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2021216660A1 (en) 2020-04-22 2021-10-28 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
EP4139000A1 (en) 2020-04-22 2023-03-01 Assembly Biosciences, Inc. Pyrazole carboxamide compounds for treatment of hbv
IL298118A (en) 2020-06-02 2023-01-01 Incyte Corp Processes for making jak1 inhibitor
WO2022010882A1 (en) 2020-07-07 2022-01-13 Enanta Pharmaceuticals, Inc, Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors
EP4192474A1 (en) 2020-08-07 2023-06-14 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CA3204374A1 (en) 2020-12-08 2022-06-16 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
WO2022206879A1 (zh) * 2021-03-31 2022-10-06 苏州晶云药物科技股份有限公司 氨磺酰基吡咯酰胺类化合物的晶型及其制备方法
TW202348237A (zh) 2021-05-13 2023-12-16 美商基利科學股份有限公司 TLR8調節化合物及抗HBV siRNA療法之組合
KR20240025616A (ko) 2021-06-23 2024-02-27 길리애드 사이언시즈, 인코포레이티드 다이아실글리세롤 키나제 조절 화합물
AU2022297367A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US20230060354A1 (en) 2021-06-23 2023-03-02 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022298639A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023069545A1 (en) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023069544A1 (en) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023069547A1 (en) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023164181A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2023164183A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2023164179A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2023164186A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv

Family Cites Families (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843662A (en) 1971-12-09 1974-10-22 Pfizer 2-halo-5-(substituted piperidino sulfonyl)benzoic acids
AU1508183A (en) 1982-06-04 1983-12-08 Beecham Group Plc Benzamide and anilide derivatives of 8-azabicyclo-(3.2.1)- -octane
WO1984003281A1 (en) 1983-02-19 1984-08-30 Beecham Group Plc Azabicycloalkyl benzamide and anilide derivatives
JPS62142164A (ja) 1985-12-13 1987-06-25 Ishihara Sangyo Kaisha Ltd ４，５−ジクロロイミダゾ−ル系化合物及びそれらを含有する有害生物防除剤
IN164880B (es) 1986-01-30 1989-06-24 Ishihara Sangyo Kaisha
US5272167A (en) 1986-12-10 1993-12-21 Schering Corporation Pharmaceutically active compounds
CA1339133C (en) 1987-03-13 1997-07-29 Rikuo Nasu Imidazole compounds and biocidal composition comprising the same for controlling harmful organisms
US5571821A (en) 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
GB8904174D0 (en) 1989-02-23 1989-04-05 British Bio Technology Compounds
US4962101A (en) 1989-08-21 1990-10-09 Merck & Co., Inc. 2-(Heterocyclylalkyl)phenyl carbapenem antibacterial agents
GB9023082D0 (en) 1990-10-24 1990-12-05 Schering Agrochemicals Ltd Fungicides
GB9109557D0 (en) 1991-05-02 1991-06-26 Wellcome Found Chemical compounds
US5308826A (en) 1993-04-22 1994-05-03 Zeneca Limited Herbicidal 4-substituted pyridyl-3-carbinols
GB9405347D0 (en) 1994-03-18 1994-05-04 Agrevo Uk Ltd Fungicides
US5795907A (en) 1994-05-27 1998-08-18 James Black Foundation Limited Gastin and CCK receptor ligands
DE69530081T2 (de) 1994-05-27 2003-12-24 Black James Foundation Gastrin- und cck-antagonisten
US5763618A (en) 1995-05-12 1998-06-09 Konica Corporation Manufacturing method of sulfides
US5723411A (en) 1995-10-31 1998-03-03 E. I. Du Pont De Nemours And Company Herbicidal pyridazinones
DE19540995A1 (de) 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9612884D0 (en) 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
EP0912550A1 (en) 1996-06-25 1999-05-06 Smithkline Beecham Plc Sulfonamide derivatives as 5ht7 receptor antagonists
AU5127098A (en) 1996-11-29 1998-06-22 Smithkline Beecham Plc Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis
US5939423A (en) 1997-04-16 1999-08-17 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US5994396A (en) 1997-08-18 1999-11-30 Centaur Pharmaceuticals, Inc. Furansulfonic acid derivatives and pharmaceutical compositions containing the same
CA2318731C (en) 1998-01-29 2012-05-29 Tularik Inc. Ppar-gamma modulators
US6410561B1 (en) 1998-03-26 2002-06-25 Japan Tobacco Inc. Amide derivatives and nociceptin antagonists
US6251893B1 (en) 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
KR100720906B1 (ko) 1999-01-15 2007-05-25 알타나 파마 아게 Ｐｄｅ-ｉｖ 억제 활성을 갖는 페닐페난트리딘
KR20020015376A (ko) 1999-07-16 2002-02-27 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ｍｅｋ 억제제를 사용한 만성 통증의 치료 방법
ES2302697T3 (es) 1999-08-10 2008-08-01 The Chancellor, Masters And Scholars Of The University Of Oxford Compuestos n-alquilicos de cadena larga y derivados oxa de los mismos y uso como composiciones antivirales.
WO2001019788A2 (en) 1999-09-17 2001-03-22 Cor Therapeutics, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
AR025884A1 (es) 1999-10-01 2002-12-18 Takeda Pharmaceutical Compuestos de amina ciclica, su produccion y su uso
OA12126A (en) 1999-12-28 2006-05-05 Pfizer Prod Inc Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune,and respiratory diseases.
WO2001055121A1 (fr) 2000-01-28 2001-08-02 Kaken Pharmaceutical Co., Ltd. Dérivés d'azépine
US6511980B2 (en) 2000-05-05 2003-01-28 Ortho Mcneil Pharmaceutical, Inc. Substituted diamine derivatives useful as motilin antagonists
EP1193268A1 (en) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases
WO2002051410A2 (en) 2000-12-22 2002-07-04 Akzo Nobel N.V. Phenylthiazole and thiazoline derivatives and their use as antiparasitics
KR100857758B1 (ko) 2000-12-27 2008-09-09 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규 카르바페넴 화합물
US7015012B2 (en) 2001-02-09 2006-03-21 Massachusetts Institute Of Technology Methods of identifying agents that mediate polypeptide aggregation
US6650463B2 (en) 2001-03-13 2003-11-18 Seiko Epson Corporation Electrophoretic display device
MXPA03009497A (es) 2001-04-19 2004-05-24 Eisai Co Ltd Derivados de 2-iminopirrolidina.
KR100713137B1 (ko) 2001-06-28 2007-05-02 동화약품공업주식회사 신규의 2,4-디플루오로벤즈아미드 유도체
SE0102315D0 (sv) * 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
DE10136043A1 (de) 2001-07-25 2003-02-13 Degussa Verfahren zur Herstellung von modifiziertem Ruß
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
ATE297925T1 (de) 2001-11-20 2005-07-15 Lilly Co Eli 3-substituierte oxindol beta 3 agonisten
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
EP1512396A4 (en) 2002-06-05 2008-12-31 Inst Med Molecular Design Inc INHIBITORS OF AP-1 AND NFAT ACTIVATION
MXPA05000130A (es) 2002-06-27 2005-02-17 Novo Nordisk As Derivados de aril-carbonilo como agentes terapeuticos.
RU2340605C2 (ru) 2002-06-27 2008-12-10 Ново Нордиск А/С Арилкарбонильные производные в качестве терапевтических средств
AU2003254177A1 (en) 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
AU2003256923A1 (en) 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
WO2004014428A1 (ja) 2002-08-09 2004-02-19 Ajinomoto Co.,Inc. 腸疾患および内臓痛の治療薬
US20040110802A1 (en) 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
RU2005106274A (ru) 2002-09-06 2005-11-10 Янссен Фармацевтика, Н.В. (Be) Гетероциклические соединения
SE0202838D0 (sv) 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
EP1590327A1 (en) 2002-12-23 2005-11-02 Millennium Pharmaceuticals, Inc. Ccr8 inhibitors
US7320989B2 (en) 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
EP1605752B1 (en) 2003-03-27 2011-09-14 Cytokinetics, Inc. Sulfonamides for the treatment of congestive heart failure, their compositions and uses.
AU2004236249A1 (en) 2003-04-30 2004-11-18 The Institutes Of Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1B
JP2006528685A (ja) 2003-05-06 2006-12-21 スミスクライン ビーチャム コーポレーション 新規化合物
ATE401328T1 (de) 2003-05-13 2008-08-15 Schering Corp Verbrückte n-arylsulfonylpiperidine als gamma- sekretaseinhibitoren
EP1651595A2 (en) 2003-05-30 2006-05-03 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US20110275630A1 (en) 2003-06-02 2011-11-10 Abbott Laboratories Isoindolinone kinase inhibitors
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
GB0319151D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
EP1678147B1 (en) 2003-09-15 2012-08-08 Lead Discovery Center GmbH Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US7498050B2 (en) 2003-12-15 2009-03-03 Kraft Foods Global Brands Llc Edible spread composition and packaged product
DE102004009238A1 (de) 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
US8404747B2 (en) 2004-03-05 2013-03-26 The General Hospital Corporation Compositions and methods for modulating interaction between polypeptides
EP1758856A2 (en) 2004-05-04 2007-03-07 Novo Nordisk A/S Indole derivatives for the treatment of obesity
US20090105218A1 (en) 2004-05-29 2009-04-23 7Tm Pharma A/S CRTH2 Receptor Ligands For Therapeutic Use
WO2006002133A1 (en) 2004-06-22 2006-01-05 Schering Corporation Cannabinoid receptor ligands
AU2005266890C1 (en) 2004-07-30 2014-09-25 Exelixis, Inc. Pyrrole derivatives as pharmaceutical agents
NZ553087A (en) 2004-08-31 2010-12-24 Astrazeneca Ab Quinazolinone derivatives and their use as B-raf inhibitors
DE102004042441A1 (de) 2004-08-31 2006-04-06 Sanofi-Aventis Deutschland Gmbh Mit Aminosäuren substituierte Hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
TW200626559A (en) 2004-10-13 2006-08-01 Wyeth Corp Anilino-pyrimidine analogs
JP2008517057A (ja) 2004-10-19 2008-05-22 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド インドールおよびベンゾイミダゾール誘導体
US7919487B2 (en) 2004-11-10 2011-04-05 Synta Pharmaceuticals Corporation Heteroaryl compounds
US20060122236A1 (en) 2004-12-06 2006-06-08 Wood Michael R Substituted biaryl-carboxylate derivatives
WO2006067445A2 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
UY29300A1 (es) 2004-12-22 2006-07-31 Astrazeneca Ab Compuestos quimicos
FI117653B (fi) 2005-02-21 2006-12-29 Eigenor Oy Menetelmä ja laitteisto liikkuvien kohteiden havaitsemiseksi tutkalla
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
BRPI0615934A2 (pt) 2005-09-16 2011-05-31 Arrow Therapeutics Ltd composto ou um sal farmaceuticamente aceitável do mesmo, uso de um derivado de bifenila, composição farmacêutica, e, produto
AU2006326494A1 (en) 2005-12-12 2007-06-21 Genelabs Technologies, Inc. N-(6-membered aromatic ring)-amido anti-viral compounds
EP1962835A2 (en) 2005-12-21 2008-09-03 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or h3 receptor antagonist/inverse agonist
WO2007073935A1 (en) 2005-12-29 2007-07-05 Lek Pharmaceuticals D.D. Heterocyclic compounds
WO2007131168A2 (en) 2006-05-04 2007-11-15 Institute For Hepatitis And Virus Research Inhibitors of secretion of hepatitis b virus antigens for treatment of a chronic hepatitis virus
US8153803B2 (en) 2006-07-18 2012-04-10 The General Hospital Corporation Compositions and methods for modulating sirtuin activity
US20080021063A1 (en) 2006-07-18 2008-01-24 Kazantsev Aleksey G Compositions and methods for modulating sirtuin activity
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
WO2008022171A1 (en) 2006-08-17 2008-02-21 Boehringer Ingelheim International Gmbh Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors
AU2007314521A1 (en) * 2006-10-06 2008-05-08 Merck Sharp & Dohme Corp. Non-nucleoside reverse transcriptase inhibitors
WO2008076270A2 (en) 2006-12-13 2008-06-26 Temple University-Of The Commonwealth System Of Higher Education Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
US20100022517A1 (en) 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
JP2008179621A (ja) 2006-12-28 2008-08-07 Taisho Pharmaceutical Co Ltd 含窒素飽和複素環化合物
JP2008184403A (ja) 2007-01-29 2008-08-14 Japan Health Science Foundation 新規ｃ型肝炎ウイルス阻害剤
CA2681162C (en) 2007-03-15 2015-11-24 Novartis Ag Benzyl and pyridine derivatives as modulators of hedgehog pathway
US8097728B2 (en) 2007-04-30 2012-01-17 Philadelphia Health & Education Corporation Iminosugar compounds with antiflavirus activity
WO2008137794A1 (en) 2007-05-04 2008-11-13 Irm Llc Compounds and compositions as c-kit and pdgfr kinase inhibitors
TW200901969A (en) * 2007-06-06 2009-01-16 Smithkline Beecham Corp Chemical compounds
WO2008154819A1 (fr) 2007-06-18 2008-12-24 Zhang, Zhongneng Thiazolyl-dihydropyrimidines à substitution carbéthoxy
WO2009018219A2 (en) 2007-07-28 2009-02-05 University Of Chicago Methods and compositions for modulating rad51 and homologous recombination
BRPI0815038A2 (pt) 2007-08-02 2015-03-17 Hoffmann La Roche Uso de derivados de benzamida para o tratamento de transtornos do cns
CN101429166B (zh) 2007-11-07 2013-08-21 上海特化医药科技有限公司 喹唑啉酮衍生物及其制备方法和用途
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
FR2926556B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
FR2926555B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives bicycliques de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926554B1 (fr) 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926553B1 (fr) 2008-01-23 2010-02-19 Sanofi Aventis Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
CU20080028A6 (es) 2008-02-29 2011-02-24 Ct Ingenieria Genetica Biotech Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus
WO2009146013A1 (en) 2008-03-31 2009-12-03 Georgetown University Myosin light chain phosphatase inhibitors
ES2527589T3 (es) 2008-04-24 2015-01-27 Msd K.K. Inhibidor de la enzima de elongación de ácidos grasos de cadena larga que comprende un derivado de arilsulfonilo como principio activo
US8410147B2 (en) 2008-06-26 2013-04-02 Inspire Pharmaceuticals, Inc. Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds
US20100008968A1 (en) 2008-06-26 2010-01-14 Lampe John W Method for treating cardiovascular diseases using rho kinase inhibitor compounds
US20090325960A1 (en) 2008-06-26 2009-12-31 Fulcher Emilee H Method for treating inflammatory diseases using rho kinase inhibitor compounds
WO2009158587A1 (en) 2008-06-26 2009-12-30 Inspire Pharmaceuticals, Inc. Method for treating pulmonary diseases using rho kinase inhibitor compounds
US8207195B2 (en) 2008-06-26 2012-06-26 Inspire Pharmaceuticals, Inc. Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds
US20090325959A1 (en) 2008-06-26 2009-12-31 Vittitow Jason L Method for treating ophthalmic diseases using rho kinase inhibitor compounds
JP2012500189A (ja) 2008-08-15 2012-01-05 エフ．ホフマン−ラ ロシュ アーゲー ビアリールアミノテトラリン
US9040488B2 (en) 2008-09-02 2015-05-26 Baruch S. Blumberg Institute Imino sugar derivatives demonstrate potent antiviral activity and reduced toxicity
US8143269B2 (en) 2008-10-03 2012-03-27 Calcimedica, Inc. Inhibitors of store operated calcium release
WO2010043592A1 (en) 2008-10-15 2010-04-22 Revotar Biopharmaceuticals Ag Lipase inhibitors for use for the treatment of obesity
UY32251A (es) 2008-11-20 2010-05-31 Glaxosmithkline Llc Compuestos quimicos
WO2010065782A1 (en) 2008-12-04 2010-06-10 Inspire Pharmaceuticals, Inc. Method for treating pulmonary diseases using rho kinase inhibitor compounds
CA2748174A1 (en) 2008-12-30 2010-07-08 Arqule, Inc. Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
WO2010088000A2 (en) 2009-02-02 2010-08-05 Angion Biomedica Corp. Antifibrotic compounds and uses thereof
WO2010123139A1 (ja) 2009-04-24 2010-10-28 持田製薬株式会社 スルファモイル基を有するアリールカルボキサミド誘導体
WO2010133336A1 (en) 2009-05-19 2010-11-25 Bayer Cropscience Ag Insecticidal arylpyrrolines
TWI574961B (zh) 2009-05-27 2017-03-21 Ｐｔｃ治療公司 治療癌症及非腫瘤病症之方法
KR20120049852A (ko) 2009-06-30 2012-05-17 시가 테크놀로지스, 인크. 뎅기 바이러스 감염의 치료 및 예방
CA2689707A1 (en) * 2009-11-16 2011-05-16 Jean-Simon Diallo Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20120252792A1 (en) 2009-09-17 2012-10-04 The Regents Of The University Of Michigan Methods and compositions for modulating rho-mediated gene transcription
WO2011058766A1 (en) 2009-11-16 2011-05-19 Raqualia Pharma Inc. Aryl carboxamide derivatives as ttx-s blockers
CN102093320B (zh) 2009-12-09 2013-08-28 扬子江药业集团上海海尼药业有限公司 一种可溶性环氧化物水解酶抑制剂
JP2013517271A (ja) 2010-01-15 2013-05-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
WO2011088561A1 (en) 2010-01-20 2011-07-28 University Of Manitoba Anti-viral compounds and compositions
WO2011109237A2 (en) 2010-03-02 2011-09-09 Emory University Uses of noscapine and derivatives in subjects diagnosed with fap
WO2011112191A1 (en) 2010-03-11 2011-09-15 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
JP2013523766A (ja) 2010-03-31 2013-06-17 グラクソ グループ リミテッド キナーゼ阻害剤としてのイミダゾリル‐イミダゾール
MX2012012966A (es) 2010-05-07 2013-01-22 Glaxosmithkline Llc Indoles.
US8993622B2 (en) 2010-06-11 2015-03-31 Eirium Ab Antiviral compounds
US20130142827A1 (en) 2010-06-25 2013-06-06 Philadelphia Health & Education Corporation D/B/A Induction of immune response
EP2595665A1 (en) 2010-07-19 2013-05-29 Inspire Pharmaceuticals, Inc. Bifunctional rho kinase inhibitor compounds, composition and use
EP2598478A2 (en) 2010-07-26 2013-06-05 Neurotherapeutics Pharma, Inc. Arylsulfonamide derivatives, compositions, and methods of use
BR112013001015A2 (pt) 2010-07-27 2016-05-24 Inspire Pharmaceuticals Inc método por tratar doenças oftálmicas que usam compostos de inibidor de cinase em formas de prodrug
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
WO2012033956A1 (en) 2010-09-08 2012-03-15 Mithridion, Inc. Cognition enhancing compounds and compositions, methods of making, and methods of treating
CN103889428A (zh) 2010-10-04 2014-06-25 肝炎与病毒研究所 乙型肝炎病毒抗原分泌的新型抑制剂
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
EP2646439B1 (en) 2010-12-02 2016-05-25 Bristol-Myers Squibb Company Alkyl amides as hiv attachment inhibitors
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
GB201103419D0 (es) 2011-02-28 2011-04-13 Univ Aberdeen
AU2012238564A1 (en) 2011-04-08 2013-09-26 Janssen Sciences Ireland Uc Pyrimidine derivatives for the treatment of viral infections
US8889716B2 (en) 2011-05-10 2014-11-18 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
US9399619B2 (en) * 2011-07-01 2016-07-26 Baruch S. Blumberg Institute Sulfamoylbenzamide derivatives as antiviral agents against HBV infection
MX359634B (es) 2011-12-21 2018-10-03 Novira Therapeutics Inc Agentes antivirales contra la hepatitis b.
ES2581489T3 (es) 2012-01-06 2016-09-06 Janssen Sciences Ireland Uc 1,4-dihidropirimidinas 4,4-disustituidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis B
WO2013130703A2 (en) 2012-02-29 2013-09-06 Institute For Hepatitis And Virus Research Binhibitors of hepatitis b virus convalently closed circular dna formation and their method of use
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
EP2831060B1 (en) 2012-03-31 2016-05-04 F.Hoffmann-La Roche Ag Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
SG11201407336PA (en) 2012-05-25 2015-03-30 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
BR112014029697A2 (pt) 2012-06-01 2017-08-08 Baruch S Blumberg Inst método para modular a transcrição de cccdna de hepatite b em um indivíduo, método para modular dna circular covalentemente fechado de vírus da hepatite b e composto
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
AR092348A1 (es) 2012-07-11 2015-04-15 Hoffmann La Roche DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc
BR112015004192B1 (pt) 2012-08-28 2021-02-09 Janssen Sciences Ireland Uc sulfamoíl-arilamidas, composição farmacêutica que os compreende e uso das mesmas no tratamento da hepatite b
EP2890683B1 (en) 2012-08-28 2016-10-12 Janssen Sciences Ireland UC Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b
WO2014037480A1 (en) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
KR101942151B1 (ko) 2012-12-27 2019-01-24 드렉셀유니버시티 Hbv 감염에 대한 항바이러스 물질
JP6466348B2 (ja) 2013-02-28 2019-02-06 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用
TWI622592B (zh) 2013-02-28 2018-05-01 衛材Ｒ＆Ｄ企管股份有限公司 四氫咪唑並［１，５－ｄ］［１，４］氧氮雜卓衍生物
WO2014165128A2 (en) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Hepatitis b antiviral agents
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
DK2981536T3 (en) 2013-04-03 2017-09-25 Janssen Sciences Ireland Uc N-PHENYLC CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
CN105960400B (zh) 2013-05-17 2019-05-31 爱尔兰詹森科学公司 氨磺酰基噻吩酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
MX2015015692A (es) 2013-05-17 2016-03-04 Hoffmann La Roche Novedosas heteroarildihidropirimidinas, unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de hepatitis b.
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
CA2913509A1 (en) 2013-05-28 2014-12-04 Bayer Cropscience Aktiengesellschaft Heterocyclic compounds as pest control agents
JP6286031B2 (ja) 2013-05-28 2018-02-28 アストラゼネカ アクチボラグ 化合物
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
EP3357906B1 (en) 2013-07-25 2019-12-04 Janssen Sciences Ireland Unlimited Company Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
WO2015057945A1 (en) 2013-10-18 2015-04-23 Indiana University Research And Technology Corporation Hepatitis b viral assembly effectors
WO2015055764A1 (en) 2013-10-18 2015-04-23 Syngenta Participations Ag 3-methanimidamid-pyridine derivatives as fungicides
CA2923712C (en) 2013-10-23 2021-11-02 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US9115113B2 (en) 2013-11-14 2015-08-25 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
JO3466B1 (ar) 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9796672B2 (en) 2014-01-31 2017-10-24 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
AU2015214096B2 (en) 2014-02-05 2021-02-11 Novira Therapeutics, Inc. Combination therapy for treatment of HBV infections
CA2932551A1 (en) 2014-02-06 2015-08-13 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
SG11201607332UA (en) 2014-03-07 2016-10-28 Hoffmann La Roche Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
HUE046567T2 (hu) 2014-03-13 2020-03-30 Univ Indiana Res & Tech Corp Hepatitis B mag protein allosztérikus modulátorok
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
KR20160133563A (ko) 2014-03-28 2016-11-22 선샤인 레이크 파르마 컴퍼니 리미티드 다이하이드로피리미딘 화합물 및 이의 약제학적 용도
US9938301B2 (en) 2014-05-30 2018-04-10 Qilu Pharmaceutical Co., Ltd. Dihydropyrimido fused ring derivative as HBV inhibitor
ES2802412T3 (es) 2014-12-02 2021-01-19 Novira Therapeutics Inc Compuestos de sulfonamida inversa a base de sulfuro, alquilo y piridilo para el tratamiento del VHB
AU2015373996B2 (en) 2014-12-30 2020-10-08 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis B infections
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
EP3271019A1 (en) 2015-03-19 2018-01-24 Novira Therapeutics Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
WO2016161268A1 (en) 2015-04-01 2016-10-06 Enanta Pharmaceuticals, Inc. Hepatitis b antviral agents
EP3283472B1 (en) 2015-04-17 2021-04-14 Indiana University Research & Technology Corporation Hepatitis b viral assembly effectors
WO2016183266A1 (en) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Ehpatitis b antiviral agents
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CA3000197A1 (en) 2015-09-29 2017-04-06 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
CN109251212A (zh) 2017-07-14 2019-01-22 上海长森药业有限公司 内环硫醚酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途

Also Published As

Publication number Publication date
WO2014184350A1 (en) 2014-11-20
DK2997011T3 (en) 2018-12-17
HRP20181544T1 (hr) 2018-11-30
SG10201607294SA (en) 2016-10-28
EP2997011A1 (en) 2016-03-23
PH12015502579B1 (en) 2016-02-29
NI201500161A (es) 2016-01-06
PL2997011T3 (pl) 2019-03-29
TW202126620A (zh) 2021-07-16
SG11201509428PA (en) 2015-12-30
CY1121391T1 (el) 2020-05-29
KR102055639B1 (ko) 2019-12-13
CY1123298T1 (el) 2021-12-31
JP2016518434A (ja) 2016-06-23
US20180141905A1 (en) 2018-05-24
TW201908289A (zh) 2019-03-01
AU2019236657A1 (en) 2019-10-17
EP3121164B1 (en) 2020-02-19
EP3594204A1 (en) 2020-01-15
PT2997011T (pt) 2018-11-30
JP6318238B2 (ja) 2018-04-25
DK3121164T3 (da) 2020-05-11
LT3121164T (lt) 2020-08-10
PH12018501812A1 (en) 2019-11-18
CN105452220B (zh) 2019-01-25
PT3121164T (pt) 2020-05-12
MX2020011810A (es) 2021-10-21
US20160115125A1 (en) 2016-04-28
MX366722B (es) 2019-07-22
EA201592200A1 (ru) 2016-03-31
EA037378B1 (ru) 2021-03-22
MX2015015770A (es) 2016-03-11
IL264541A (en) 2019-02-28
KR20160008574A (ko) 2016-01-22
UA117246C2 (uk) 2018-07-10
ME03787B (me) 2021-04-20
HK1218117A1 (zh) 2017-02-03
KR20210025712A (ko) 2021-03-09
HRP20200648T1 (hr) 2020-07-10
KR102223535B1 (ko) 2021-03-08
ZA201508443B (en) 2020-08-26
CN110003076A (zh) 2019-07-12
JP2020117530A (ja) 2020-08-06
SI2997011T1 (sl) 2018-11-30
JO3583B1 (ar) 2020-07-05
TWI651300B (zh) 2019-02-21
ES2787704T3 (es) 2020-10-16
AU2021206827A1 (en) 2021-08-12
IL264541B (en) 2019-09-26
AU2019236657B2 (en) 2021-05-20
GT201500312A (es) 2018-01-17
SG10201607293UA (en) 2016-10-28
SI3121164T1 (sl) 2020-06-30
PH12015502579A1 (en) 2016-02-29
TWI733288B (zh) 2021-07-11
LT2997011T (lt) 2018-10-25
KR101867898B1 (ko) 2018-06-15
UY35573A (es) 2014-11-28
CA2909348C (en) 2019-01-08
CN105452220A (zh) 2016-03-30
EP3121164A1 (en) 2017-01-25
SG10202002604PA (en) 2020-05-28
AU2017276170B2 (en) 2019-07-11
ES2699261T3 (es) 2019-02-08
ECSP15048122A (es) 2017-02-24
TW201522305A (zh) 2015-06-16
US10457638B2 (en) 2019-10-29
NZ713201A (en) 2021-03-26
KR20190139328A (ko) 2019-12-17
IL260597B (en) 2019-03-31
PL3121164T3 (pl) 2020-07-27
TW202017903A (zh) 2020-05-16
MX2019008585A (es) 2019-09-19
HUE050236T2 (hu) 2020-11-30
AU2014267220B2 (en) 2017-09-28
RS60285B1 (sr) 2020-06-30
RS58140B1 (sr) 2019-02-28
CA2909348A1 (en) 2014-11-20
HUE039997T2 (hu) 2019-02-28
JP2018118990A (ja) 2018-08-02
KR20180066279A (ko) 2018-06-18
AU2017276170A1 (en) 2018-01-18
BR112015028461A2 (pt) 2017-07-25
US20200039931A1 (en) 2020-02-06
JO3603B1 (ar) 2020-07-05
TWI684586B (zh) 2020-02-11
AU2014267220A1 (en) 2015-11-05
EP2997011B1 (en) 2018-08-29
US9884818B2 (en) 2018-02-06

Similar Documents

Publication Publication Date Title
CL2015003370A1 (es) Derivados de sulfamoilpirrolamiday su uso como medicamentos para el tratamiento de la hepatitis b
CL2016001936A1 (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
CO2017012268A2 (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016000493A1 (es) Inhibidores de polimerasa hcv.
CL2016000952A1 (es) Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016000381A1 (es) Compuestos antivirales
CL2017001798A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas.
GT201500020A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2015003615A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
UY37252A (es) Compuestos para el tratamiento de infección por virus de la hepatitis b
CL2016001120A1 (es) Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct
CL2014003634A1 (es) Inhibidores del virus de la hepatitis c
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
CL2015001916A1 (es) Derivados de pirimidona y su uso en el tratamiento, mejora o prevención de una enfermedad viral.
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
CL2012001959A1 (es) Compuestos derivados del acido tiofeno-2-carboxilico, inhibidores de virus flaviviridae; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral por flaviviridae.
CL2014000394A1 (es) Uso de compuestos fenil-benzofuran-sulfamido sustituidos para el tratamiento del virus de la hepatitis c (hcv); y composicion farmaceutica que comprende a estos compuestos fenil-benzofuran-sulfamido sustituidos.
CL2015003358A1 (es) Compuestos derivados de nucleósidos 4'-azido-3'-desoxi-3'-fluoro sustituidos; composición farmacéutica que comprende a dichos compuestos y el uso de los mismos para tratar una infección del virus de la hepatitis c (hcv).
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
CL2015003752A1 (es) Inhibidores de replicación viral, su proceso de preparación y sus uso terapeutico